[Skip to Content]
[Skip to Content Landing]
January 1995

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients

Author Affiliations

From the Western Psychiatric Institute and Clinic, University of Pittsburgh (Pa0 School of Medicine. Dr McEvoy is now with the Duke University Medical Center, Durham, NC, and Dr Munetz is now with the Northeastern Ohio Universities College of Medicine, Rootstown.

Arch Gen Psychiatry. 1995;52(1):29-41. doi:10.1001/archpsyc.1995.03950130029004

Background:  Prominent and persistent anxiety, depression, and/or negative features characterize a substantial minority of recovered or residually psychotic schizophrenic outpatients and contribute to poor outcome. Because extrapyramidal side effects of typical neuroleptic medications often resemble such features, we first systematically studied the contribution of extrapyramidal side effects to these problems and their treatment. For patients who remained distressed, controlled trials of supplemental thymoleptics were undertaken.

Methods:  In trial 1, 92 distressed (depressed and/or anxious) patients and 36 patients in a defect state (patients with negative symptoms) participated in a double-blind, intramuscular challenge that compared centrally acting benztropine mesylate with peripherally acting glycopyrrolate. In trial 2,57 distressed patients and 22 patients in a defect state were randomly assigned to a double-blind, neuroleptic medication dose-reduction group. In trial 3,57 chronically distressed patients who were maintained on a low dose of fluphenazine decanoate were randomly assigned to a supplemental desipramine hydrochloride, lithium carbonate, or placebo group under double-blind conditions for 12 weeks.

Results:  For patients who were already maintained on antiparkinsonian medication, impaired affect was not resolved by additional benztropine. Only distressed patients with a family history of severe mental disorder (often affective) showed improvement with neuroleptic medication dose reduction. Patients in the defect-state group reported less dysphoria on a reduced neuroleptic medication dose, but negative symptoms persisted. Desipramine improved diverse aspects of mood and residual psychoticism, possibly as a prophylaxis against minor affective exacerbations. Depression improved in women only. Lithium positively affected multiple indexes of anxiety and anxious depression.

Conclusion:  Most often, persistent affective impairments are neither resistant extrapyramidal side effects nor characterological traits. Thymoleptics improve the non-phasic, chronic types of anxiety and depression in contrast to the acute, episodic forms, for which little support can be found in the literature.